ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 19, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that the Company will present in a fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023 at 12:00 p.m. ET. Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Executive Officer, and Daniel Steiner, SVP Research.
A live webcast of the event will be available on the "News and Events" page in the "Events" section of the Company's website. A replay of the webcast will be archived on the Company's website for 1 year following their respective presentation dates.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin (designed ankyrin repeat protein) therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and virology and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com Find us on Twitter - @MolecularPrtnrs
For further details, please contact:
Seth Lewis, Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +1 781 420 2361
Antonio Ligi, Communications
Zurich-Schlieren, Switzerland
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +41 79 723 36 81
| Last Trade: | US$3.73 |
| Daily Change: | -0.06 -1.58 |
| Daily Volume: | 3,270 |
| Market Cap: | US$139.460M |
August 25, 2025 August 21, 2025 June 22, 2025 June 11, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
